Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AVTX
AVALO THERAPEUTICS, INC.
NASDAQ
$19.00
▼ DOWN 1.76% (-0.34)

KEY STATISTICS

Market Cap$993.91 M
52w High$24.27
52w Low$9.54
Dividend Yield—
Frequency—
P/E-4.01
Volume674.02K
Shares Out.52.57M

COMPANY

LEADERSHIP

Garry A. Neil
CHIEF EXECUTIVE
Garry A. Neil

COMPENSATION 2026

Salary$590,000
Stock Awards$0
Incentive Plan Pay$474,950
All Other Comp.$10,333
Total$3,807,581

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 14, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
33

PRICE TARGET

Target High$60.00
Target Low$30.00
Target Median$46.50
Target Consensus$45.13

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2023-12-29Reverse1:240
2022-07-08Reverse1:12

PRICE

$19.00 ▼ DOWN 1.76% (−$0.34)
OVERLAYS
$18.90$19.05$19.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM19.00

About Avalo Therapeutics, Inc.

https://www.avalotx.com ↗

Avalo Therapeutics is a clinical-stage biotech developing targeted therapies for immunology, immuno-oncology, and rare genetic diseases, with several drugs in Phase I-III trials including anti-LIGHT and anti-IL-18 antibodies.

INDUSTRY

Biotechnology

A PRODUCT AVALO THERAPEUTICS, INC. IS KNOWN FOR

AVTX-009
AVTX-009

AVTX-009, Avalo Therapeutics' lead monoclonal antibody targeting IL-1β, is in Phase 2 trials for moderate to severe hidradenitis suppurativa.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
JNJ COMPARE
NVS COMPARE
UCB COMPARE

Revenue by Products

IconPRODUCTQ3-2023Q4-2023Q3-2024Q4-2024
Product$236K $54K ▼$249K ▲$192K ▼
License$0 — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
85
LISTED HERE
17
RANKED BY POSITION SIZE
XBI
0.35% · 2.1M
VTS.AX
0.00% · 1.7M
XSU.TO
0.03% · 1.1M
FESM
0.07% · 220.4K
LABU
0.24% · 72.2K
XRSG.L
0.03% · 38.3K
BBC
0.82% · 21.3K
RSSL
0.03% · 20.0K
GSSC
0.04% · 19.8K
AVSC
0.01% · 12.0K
URTY
0.01% · 1.7K
PWS
0.07% · 942
TNXT
0.04% · 430
USUE.DE
0.00% · 217
DXUV
0.00% · 140
RESM
0.03% · 94
SC0K.DE
0.03% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
33.51%
HOLDERS
129
TOP 12 OF 129 · RANKED BY POSITION SIZE
Fmr LLC
2.9M sh · $42.99M
T. Rowe Price Investment Management, Inc.
2.2M sh · $32.29M
Caligan Partners LP
1.6M sh · $24.41M
Bvf Inc/Il
1.6M sh · $24.38M
Avoro Capital Advisors LLC
1.4M sh · $21.05M
Orbimed Advisors LLC
1.3M sh · $17.15M
Affinity Asset Advisors, LLC
1.3M sh · $20.02M
Nantahala Capital Management, LLC
1.2M sh · $18.44M
Ubs Group AG
1.1M sh · $17.05M
Point72 Asset Management, L.P.
1.1M sh · $13.4M
Farallon Capital Management LLC
916.0K sh · $13.68M
Rtw Investments, LP
857.0K sh · $12.79M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Doyle Mittie
Sale · 679 shares
2026-08-28
★
OFFICER: CHIEF MEDICAL OFFICER
Doyle Mittie
Purchase · 679 shares
2026-08-28
★
OFFICER: CHIEF FINANCIAL OFFICER
Sullivan Christopher Ryan
Sale · 31.0K shares
2026-08-18
★
OFFICER: CHIEF FINANCIAL OFFICER
Sullivan Christopher Ryan
Purchase · 2.9K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 2
MARKET OUTPERFORM 1
OVERWEIGHT 1
7 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Guggenheim BUY BTIG BUY Wedbush OUTPERFORM Mizuho OUTPERFORM Citizens MARKET OUTPERFORM Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
PRLD$5.19COMPARE
ENTA$13.93COMPARE
OBIO$4.79COMPARE
IVA$4.83COMPARE
EPRX$7.48COMPARE
CHRS$1.37COMPARE
TNYA$0.71COMPARE
CRBU$1.54COMPARE